清肺排毒汤治疗急性期新型冠状病毒肺炎对其患者后遗症的影响:回顾性队列研究

注册号:

Registration number:

ITMCTR2100004781

最近更新日期:

Date of Last Refreshed on:

2021-04-25

注册时间:

Date of Registration:

2021-04-25

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

清肺排毒汤治疗急性期新型冠状病毒肺炎对其患者后遗症的影响:回顾性队列研究

Public title:

The long-term effecs of COVID-19 after Qingfei paidu decoction treatment in acute phase: a retrospective cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

清肺排毒汤治疗急性期新型冠状病毒肺炎对其患者后遗症的影响:回顾性队列研究

Scientific title:

The long-term effecs of COVID-19 after Qingfei paidu decoction treatment in acute phase: a retrospective cohort study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100045787 ; ChiMCTR2100004781

申请注册联系人:

崔寒尽

研究负责人:

范荣

Applicant:

Cui Hanjin

Study leader:

Fan Rong

申请注册联系人电话:

Applicant telephone:

+86 13787123626

研究负责人电话:

Study leader's telephone:

+86 13808454319

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cuihanjin@csu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

fanrong3463@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市开福区湘雅路87号

研究负责人通讯地址:

湖南省长沙市开福区湘雅路87号

Applicant address:

87 Xiangya Road, Kaifu District, Changsha, Hu'nan

Study leader's address:

Xiangya Road, Kaifu District, Changsha, Hu'nan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅医院

Applicant's institution:

Xiangya Hospital, Central South University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

202003049

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中南大学湘雅医院临床医学伦理委员会

Name of the ethic committee:

Ethics committee of Xiangya Hospital of Central South University

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

肖佩君

Contact Name of the ethic committee:

Xiao Peijun

伦理委员会联系地址:

湖南省长沙市开福区湘雅路87号湘雅医院药学楼104

Contact Address of the ethic committee:

Room 104, Pharmacy Building, Xiangya Hospitial, 87 Xiangya Road, Kaifu District, Changsha, Hu'nan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中南大学湘雅医院

Primary sponsor:

Xiangya Hospital, Central South University

研究实施负责(组长)单位地址:

湖南省长沙市开福区湘雅路87号

Primary sponsor's address:

87 Xiangya Road, Kaifu District, Changsha, Hu'nan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hu'nan

City:

Changsha

单位(医院):

中南大学湘雅医院

具体地址:

开福区湘雅路87号

Institution
hospital:

Xiangya Hospital, Central South University

Address:

87 Xiangya Road, Kaifu District

经费或物资来源:

全国名老中医药专家传承工作室经费

Source(s) of funding:

Funding for inheritance studio of national famous and old TCM experts

研究疾病:

新型冠状病毒肺炎

研究疾病代码:

Target disease:

COVID-19

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

II-III期临床试验

Phase II-III clinical trial

研究目的:

观察新型冠状病毒肺炎急性期接受清肺排毒汤治疗的患者后遗症的发生情况。

Objectives of Study:

To observe the long-term effecs of COVID-19 after Qingfei paidu decoction treatment in acute phase.

药物成份或治疗方案详述:

曾接受过清肺排毒汤治疗。

Description for medicine or protocol of treatment in detail:

Patients treated by Qingfei paidu decoction.

纳入标准:

1.符合《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》中诊断标准; 2.年龄>18 岁; 3.患者知情同意; 4.有疲劳、头痛、注意力障碍、脱发、呼吸困难、心理精神障碍等后遗症的出现,且持续时间大于6个月。

Inclusion criteria

1.In line with the diagnostic criteria for New Coronavirus infection (trial version sixth); 2.Aged > 18 years; 3.Patients informed consent; 4.There were fatigue, headache, attention disorder, hair loss, dyspnea, mental disorders and other sequelae, and the duration was more than 6 months.

排除标准:

1.合并严重的精神疾病或镇静状态; 2.在研究期间出现危及生命的共病。

Exclusion criteria:

1.Those who are combined with severe mental illness, mental disorder or sedation; 2.Those who suffer fatal co-morbidities within the study follow-up period.

研究实施时间:

Study execute time:

From 2021-05-01

To      2021-09-30

征募观察对象时间:

Recruiting time:

From 2021-05-01

To      2021-07-31

干预措施:

Interventions:

组别:

未接受清肺排毒汤或其它中药治疗

样本量:

314

Group:

Without Any Traditionl Chinese Herbs

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

清肺排毒汤治疗组

样本量:

314

Group:

Qingfeipaidu Decoction group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 628

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hu'nan

City:

单位(医院):

湘雅医院

单位级别:

公立三甲

Institution/hospital:

Xiangya Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

恢复率

指标类型:

主要指标

Outcome:

Recovery Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究完成后6个月内公开于中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open to the China Clinical Trial Registration Center within 6 months after the completion of the trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例记录表,数据管理使用ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case records are used for data collection and ResMan is used for data management

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统